NKTR-262

Nektar begins Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 With CD122-Biased Agonist NKTR-214 in Patients With Advanced Solid Tumors
CP Wire
Wed, 04/11/18 - 09:36 am
Nektar Therapeutics
NKTR-214
NKTR-262
cancer
solid tumors
Nektar begins Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 With CD122-Biased Agonist NKTR-214 in Patients With Advanced Solid Tumors
Wed, 04/11/18 - 09:18 am
Nektar
NKTR-214
NKTR-262